Anxiety disorders in pregnancy and the postnatal period

There is now growing realisation that many women suffer from either new onset or worsening of existing anxiety disorders during pregnancy and postnatally.

BAVANISHA VYTHILINGUM, FCPsyCh
Department of Psychiatry, University of Cape Town

Dr Bavi Vythilingum is a senior specialist and head of the division of consultation liaison psychiatry and women’s mental health in the Department of Psychiatry, University of Cape Town. She is also the current chair of the Postnatal Depression Support Association of South Africa. Her clinical and research interests include the effects of psychosocial stress and mental illness during pregnancy on obstetric and infant outcomes.
E-mail: bavanisha.vythilingum@uct.ac.za

Studies of anxiety in pregnancy show that a significant portion of women are affected.

Epidemiology
Studies of anxiety in pregnancy show that a significant portion of women are affected. Heron et al., in a large community sample of pregnant women, found that 21% had clinically significant anxiety symptoms and, of these, 64% continued to have anxiety postnatally. Other studies have also shown higher prevalence rates of anxiety disorders in pregnancy compared with the general population.

Panic disorder
The risk of new-onset panic disorder in pregnancy per se is not known. However, recent data suggest that pregnancy may confer some kind of protection against new-onset panic disorder. In contrast, the early postpartum period is reported to be a time of increased vulnerability to panic disorder, with figures ranging from 0.5% to 1.5% at 6 weeks postpartum.

Obsessive compulsive disorder
Current data suggest that the perinatal period is a time of high risk for the onset of OCD, with studies reporting that up to 40% of women of childbearing age have onset of symptoms during this period. Data on the course of OCD during pregnancy show conflicting results.

Post-traumatic stress disorder (PTSD)
There are no data on the course of existing PTSD during pregnancy. Perinatal PTSD, that is PTSD related to medical procedures, childbirth or other obstetric events, has been reported. One study found that 20% of women reported traumatic pregnancy-related procedures, and of these 6% met criteria for PTSD. Controversy exists as to whether medical procedures during pregnancy and/or childbirth meet DSM IV criteria for a traumatic event. Risk factors for traumatic stress following childbirth include previous adverse reproductive events such as ectopic pregnancy, miscarriage, stillbirth, unwanted pregnancy and abortion, history of sexual trauma, past traumatic experience, prior psychiatric history, obstetric interventions or complications, and poor social support.

Generalised anxiety disorder (GAD)
There are few data on the epidemiology of GAD during pregnancy and postnatally. The data that do exist suggest that it is common – Wenzel and colleagues found that 4.4% of the women in their study met diagnostic criteria for GAD and that over 30% reported subsyndromal symptoms. There are no data on the course of pre-existing GAD in pregnancy. Diagnosing GAD poses special challenges in pregnancy – it is normal to have a degree of worry and anxiety in pregnancy. There are no data on specific worry domains that may be linked to GAD in pregnancy. Functional impairment and worry without a trigger may be useful in making a diagnosis.

Clinical features
The clinical features of anxiety disorders in pregnancy and postnatally are similar to those in non-pregnant women. However, concerns over the pregnancy and the infant may present as the predominant feature. For example, in panic disorder, women may interpret panic attacks as something being wrong with the fetus. Women with anxiety disorders also commonly present with physical complaints, with studies showing an increased frequency of nausea and vomiting, disability days and physician
visits in women with anxiety and/or mood disorders. Indeed, frequent physical complaints with no discernable physical cause should prompt the clinician to screen for an anxiety disorder.

**Risk of anxiety disorders in pregnancy and postnatally**

**Maternal risks**

The majority of anxiety disorders in pregnancy have a continued postnatal course. Further, several prospective studies have shown that a prenatal anxiety disorder is one of the strongest risk factors for developing postnatal depression. An anxiety disorder in pregnancy may therefore be associated with significant maternal morbidity.

**Fetal effects of maternal anxiety**

Both animal and human studies suggest that antenatal stress/anxiety causes poorer obstetric outcomes and a range of neurobehavioural problems in exposed infants. Women reporting high levels of subjective stress have been found to be at doubled risk for delivering a preterm or growth-restricted baby. Antenatal anxiety or stress has been linked with physical defects in the child and low birth weight. More worryingly, prenatal maternal anxiety has been linked with persisting neurobehavioural problems, including poorer performance on tests of neurodevelopment, increased fearfulness and conduct problems.

**... pregnancy may confer some kind of protection against new-onset panic disorder.**

**Postnatal effects of maternal anxiety**

Intense postnatal anxiety impairs maternal functioning, causes significant distress and may seriously disturb mother-infant interaction, with consequences ranging from maternal neglect and failure to thrive to infanticide.

**Screening for anxiety disorders in pregnancy**

Screening for depression in pregnancy has been well validated, and several established screening programmes exist. A strong case can be made for extending these programmes to detect anxiety disorders in pregnancy and postnatally as well. The most commonly used screening tool for depression during the perinatal period is the Edinburgh Postnatal Depression Scale (EPDS), called the Edinburgh Depression Scale (EDS) when used during pregnancy. It is probable that the EDS can also identify a number of women with anxiety disorders. It has been recommended that use of the EDS in combination with a risk questionnaire (assessing alcohol and drug use, partner and social support and domestic violence) is the optimal model for screening for both anxiety and depression in pregnancy.

**Management of anxiety disorders in pregnancy**

**Preconceptual counselling**

Ideally all women known to have an anxiety disorder should have preconception psycho-education. This should include discussing the risk of relapse during pregnancy and the postnatal period, the risks versus benefits of medications if the patient were to become pregnant and/or breastfeed, and a discussion around partner and psychosocial support during pregnancy and once the baby is born. It is essential to ask about the contraception the patient is using.

**Psychotherapy**

Psychotherapy is considered the first-choice intervention for mild to moderate anxiety disorders in the perinatal period. It poses minimal risk to the infant. While there are no studies addressing the efficacy of psychotherapy in pregnancy, studies in non-pregnant women show efficacy of both interpersonal and cognitive behavioural therapy (CBT). Relaxation and supportive therapy is also effective in treating anxiety disorders in the perinatal period.

**Pharmacotherapy**

When considering medication in pregnancy and postnatally, one needs to consider possible effects on the infant. Two classes of medication are commonly used to treat anxiety – antidepressants (including selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs)) and benzodiazepines.

**Selective serotonin reuptake inhibitors**

Selective serotonin reuptake inhibitors are the first-line pharmacotherapy for anxiety disorders in the general population. Large population-based studies have found no increase in the rates of major congenital malformations in infants exposed to SSRIs, with the exception of paroxetine, which has been associated with an increased risk for fetal ventricular and/or atrial septal defects with first-trimester exposure. Paroxetine is consequently best avoided during pregnancy. Furthermore, no long-term behavioural effects have been found in exposed infants.

A concern around SSRI use in pregnancy is the possible increased risk of persistent pulmonary hypertension of the newborn (PPHN), which occurs in 1 - 2 infants per 1 000 live births. Third-trimester exposure to fluoxetine was associated with an increased rate of PPHN (OR 6.1) in a study that controlled for maternal smoking, body mass index, and diabetes. It is not clear whether this risk is specific to fluoxetine or is associated with all SSRIs.

Infants of women who need to take SSRIs just before delivery can develop toxicity or withdrawal syndromes. Discontinuation syndromes can occur within a few hours or days after birth and last up to 1 month after delivery, depending on the infant’s susceptibility. Most suspected SSRI-induced neonatal withdrawal syndromes have been associated with paroxetine, although all SSRIs appear to be associated with some risk. Affected infants are tremulous, jittery, irritable, have poor sucking, high-pitched cries and show sleep and gastrointestinal disturbances.

Tapering and stopping SSRI use prior to the third trimester is an option that would prevent these syndromes and also decrease the risk for PPHN. However, this must be weighed up against the risk of relapse if medication is stopped. Benzodiazepine cover may be useful during this period. Medication should be started immediately after delivery to decrease risk of postpartum relapse. If a withdrawal syndrome is present, breastfeeding may help ameliorate this, by providing smaller regular exposures to SSRIs.

SSRIs are excreted in breastmilk, though in very small amounts, and breastfeeding poses little risk to the infant. Mothers who do breastfeed on SSRIs should be warned to seek help if the infant becomes excessively sleepy or lethargic.

**Tricyclic antidepressants (TCAs)**

Clomipramine and imipramine are the most commonly used drugs of this class in the management of anxiety. No increased teratogenic risk has been found with these agents. However, due to their more adverse side-effect profile, particularly postural hypotension, which can be a significant problem in a pregnant patient, and lethality in overdose, they are generally used as second-line agents. TCAs are generally considered safe during breastfeeding.
**Anxiety**

**Benodiazepines**

Benodiazepines provide immediate symptomatic relief and can be used alone or in conjunction with an antidepressant for long-term treatment, but the risk of dependence must be borne in mind.

Benodiazepine teratogenicity remains controversial. Some, but not all, data show a small but significant increased risk for major malformations/oral cleft malformations with first-trimester benodiazepine exposure.

Benodiazepines also have fetal effects. Neonatal toxicity (‘floppy infant syndrome’), characterised by hypotonia, lethargy, poor respiratory effort and feeding difficulties, occurs after maternal benodiazepine use just before delivery. Neonatal withdrawal may be caused by very late, third-trimester exposure to benodiazepines. Symptoms (which can persist ≤3 months after delivery) include restlessness, irritability, abnormal sleep patterns, sucking difficulties, growth retardation, hypotonia, hyperreflexia, tremulousness, apnoea, diarrhoea and vomiting. It is not clear however whether this is entirely due to withdrawal per se or whether ongoing exposure via breastmilk plays a role in these symptoms.

**Psychosocial issues**

Poor marital relationships and lack of social support are consistent psychosocial predictors of anxiety symptoms during pregnancy and postnatally. Family or marital therapy should therefore be considered when appropriate. In addition, antenatal childbirth education should be suggested as this has beneficial effects on mastery and maternal role satisfaction has been found. Antenatal education also provides an opportunity to link women with anxiety disorders to empathetic obstetric care providers who in turn are additional sources of support.

**Conclusion**

Anxiety disorders occur commonly in pregnancy and postnatally and have persisting consequences for both mother and baby. Effective treatments are available for the anxiety disorders and most can be used safely in the perinatal period. It is therefore important for practitioners to recognise these disorders, and to institute appropriate treatment.

**References**


**In a nutshell**

- Anxiety disorders are common during pregnancy and postnatally.
- Women with perinatal anxiety disorders commonly present with excessive concerns about the pregnancy, fetus or infant.
- Perinatal anxiety disorders can be incapacitating.
- They may have long-term effects on the infant, ranging from preterm delivery, poorer growth to neurobehavioural changes.
- Psychotherapy is the first-line treatment for anxiety in pregnancy and postnatally.
- SSRIs (other than paroxetine) and TCAs can be used during pregnancy.
- Benodiazepines should be avoided in the first trimester, as well as during the late third trimester and while breastfeeding.
- Psychosocial support for women with perinatal anxiety disorders is important.